435 related articles for article (PubMed ID: 16301635)
1. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors.
Bermúdez-Humarán LG; Cortes-Perez NG; Lefèvre F; Guimarães V; Rabot S; Alcocer-Gonzalez JM; Gratadoux JJ; Rodriguez-Padilla C; Tamez-Guerra RS; Corthier G; Gruss A; Langella P
J Immunol; 2005 Dec; 175(11):7297-302. PubMed ID: 16301635
[TBL] [Abstract][Full Text] [Related]
2. An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci.
Bermúdez-Humarán LG; Cortes-Perez NG; Le Loir Y; Alcocer-González JM; Tamez-Guerra RS; de Oca-Luna RM; Langella P
J Med Microbiol; 2004 May; 53(Pt 5):427-433. PubMed ID: 15096553
[TBL] [Abstract][Full Text] [Related]
3. Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site.
Lamikanra A; Pan ZK; Isaacs SN; Wu TC; Paterson Y
J Virol; 2001 Oct; 75(20):9654-64. PubMed ID: 11559797
[TBL] [Abstract][Full Text] [Related]
4. Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria.
Cortes-Perez NG; Lefèvre F; Corthier G; Adel-Patient K; Langella P; Bermúdez-Humarán LG
Vaccine; 2007 Sep; 25(36):6581-8. PubMed ID: 17675182
[TBL] [Abstract][Full Text] [Related]
5. Protection against human papillomavirus type 16-induced tumors in C57BL/6 mice by mucosal vaccination with Lactococcus lactis NZ9000 expressing E6 oncoprotein.
Taghinezhad-S S; Mohseni AH; Keyvani H; Razavilar V
Microb Pathog; 2019 Jan; 126():149-156. PubMed ID: 30391536
[TBL] [Abstract][Full Text] [Related]
6. A Genetically Modified attenuated
Jia YY; Tan WJ; Duan FF; Pan ZM; Chen X; Yin YL; Jiao XA
Front Cell Infect Microbiol; 2017; 7():279. PubMed ID: 28706878
[TBL] [Abstract][Full Text] [Related]
7. Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity to human papillomavirus 16-associated tumor.
Jin HS; Park EK; Lee JM; NamKoong SE; Kim DG; Lee YJ; Jun HJ; Han BD; Bae SM; Ahn WS
Gynecol Oncol; 2005 May; 97(2):559-67. PubMed ID: 15863160
[TBL] [Abstract][Full Text] [Related]
8. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.
Zwaveling S; Ferreira Mota SC; Nouta J; Johnson M; Lipford GB; Offringa R; van der Burg SH; Melief CJ
J Immunol; 2002 Jul; 169(1):350-8. PubMed ID: 12077264
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.
Chu NR; Wu HB; Wu T; Boux LJ; Siegel MI; Mizzen LA
Clin Exp Immunol; 2000 Aug; 121(2):216-25. PubMed ID: 10931134
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model.
Jia Y; Yin Y; Duan F; Fu H; Hu M; Gao Y; Pan Z; Jiao X
Int J Mol Med; 2012 Dec; 30(6):1335-42. PubMed ID: 23027427
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects.
Lee SY; Kang TH; Knoff J; Huang Z; Soong RS; Alvarez RD; Hung CF; Wu TC
Cancer Immunol Immunother; 2013 Jul; 62(7):1175-85. PubMed ID: 23615841
[TBL] [Abstract][Full Text] [Related]
12. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
Li YL; Qiu XH; Shen C; Liu JN; Zhang J
Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
[TBL] [Abstract][Full Text] [Related]
13. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
14. Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection.
Manuri PR; Nehete B; Nehete PN; Reisenauer R; Wardell S; Courtney AN; Gambhira R; Lomada D; Chopra AK; Sastry KJ
Vaccine; 2007 Apr; 25(17):3302-10. PubMed ID: 17291642
[TBL] [Abstract][Full Text] [Related]
15. Oral immunization with recombinant Lactococcus lactis NZ9000 expressing human papillomavirus type 16 E7 antigen and evaluation of its immune effects in female C57BL/6 mice.
Mohseni AH; Razavilar V; Keyvani H; Razavi MR; Khavari-Nejad RA
J Med Virol; 2019 Feb; 91(2):296-307. PubMed ID: 30192395
[TBL] [Abstract][Full Text] [Related]
16. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
Seo SH; Jin HT; Park SH; Youn JI; Sung YC
Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
[TBL] [Abstract][Full Text] [Related]
17. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
[TBL] [Abstract][Full Text] [Related]
18. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines.
Chen CH; Wang TL; Hung CF; Pardoll DM; Wu TC
Vaccine; 2000 Apr; 18(19):2015-22. PubMed ID: 10706963
[TBL] [Abstract][Full Text] [Related]
19. Suppression of antitumour protective cytotoxic T lymphocyte responses to a human papillomavirus 16 E7 DNA vaccine by coinjection of interleukin-12 complementary DNA: involvement of nitric oxide in immune suppression.
Sin JI
Immunology; 2009 Sep; 128(1 Suppl):e707-17. PubMed ID: 19740332
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine.
Smalley Rumfield C; Pellom ST; Morillon Ii YM; Schlom J; Jochems C
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
